Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Letong, Li, Yuchen, Tan, Jiaxiong, Xu, Ling, Li, Yangqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478462/
https://www.ncbi.nlm.nih.gov/pubmed/37670328
http://dx.doi.org/10.1186/s13045-023-01499-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478462/
https://www.ncbi.nlm.nih.gov/pubmed/37670328
http://dx.doi.org/10.1186/s13045-023-01499-1

Ejemplares similares